Progressive accumulation of lanthanum in the liver of normal and uremic rats

Kidney International

Volumn 68, Issue 6, 2005, Pages 2809-2813

  Slatopolsky, Eduardo ^a   Liapis, Helen ^a   Finch, Jane ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lanthanum; Phosphate binder; Phosphorus; Renal failure; Secondary hyperparathyroidism; Vascular calcification

Indexed keywords

LANTHANUM; LANTHANUM CARBONATE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG LIVER LEVEL; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE ABSORPTION; UREMIA;

ANIMAL FEED; ANIMALS; CREATININE; FEMALE; FEMUR; HYPERPARATHYROIDISM, SECONDARY; KIDNEY; KIDNEY FAILURE, CHRONIC; LANTHANUM; LIVER; PHOSPHORUS; RATS; RATS, SPRAGUE-DAWLEY; UREMIA;

EID: 32844457995     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00753.x     Document Type: Article

References (31)

1. SLATOPOLSKY E, FINCH J, DENDA M, et al: Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97:2534-2540, 1996
2. SLATOPOLSKY E, BROWN AJ, Dusso A: Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 37(Suppl 2):S54-57, 2001
3. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
4. SCHWARZ U, BUZELLO M, RITZ, et al: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218-223, 2000
5. RAGGI P, BOULAY A, CHASAN-TABER S, et al: Cardiac calcification in adult hemodialysis patients: A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39: 695-701, 2002
6. FOLEY RN, PARFREY PS, SARNAK MI: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32(Suppl 3):S112-S119, 1998
7. UNITED STATES RENAL DATA SYSTEM: Annual Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1999
8. BLOCK GA, PORT FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35:1226-1237, 2002
9. BLOCK GA, KLASSEN PS, LAZARUS JM, et al: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218, 2004
10. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001
11. GOODMAN WG: Bone disease and aluminum: Pathogenic considerations. Am J Kidney Dis 6:330-335, 1985
12. MAYOR GH: Aluminum and dialysis dementia. Ann Intern Med 91:497-498, 1979
13. SIDEMAN S, MANOR D: The dialysis dementia syndrome and aluminum intoxication. Nephron 131:1-10, 1982
14. GUERIN AP, LONDON GM, MARCHAIS SJ, METIVIER F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15:1014-1021, 2000
15. CHERTOW GM BURKE SK, LAZARUS JM, et al: Poly[allylamine hydrochloride] (Renagel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66-71, 1997
16. CHERTOW GM, BURKE SK, RAGGI P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-52, 2002
17. CHERTOW GM, BURKE SK, DILLON MA, SLATOPOLSKY E: Long term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 14:2907-2914, 1999
18. WILKES BM, REINER D, KERN M, BURKE S: Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (Renagel) in dialysis patients. Clin Nephrol 50:381-386, 1998
19. D'HAESE PC, SPASOVSKI GB, SIKOLE A, et al: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int (Suppl 85):S73-78, 2003
20. BEHETS GJ, VERBERCKMOES SC, D'HAESE PC, DE BROE ME: Lanthanum carbonate: A new phosphate binder. Curr Opin Nephrol Hypertens 13:403-409, 2004
21. DAS T, SHARMA A, TALUKDER G: Effects of lanthanum in cellular systems. Biol Trace Elem Res 18:201-28, 1988
22. KADAS T, JOBST K: Liver damage induced by lanthanum trichloride. Acta Morphologica Acad Sci Hung 21:27-37, 1973
23. LACOUR B, LUCAS A, AUCHERE D, et al: Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 67:1062-1069, 2005
24. SACCHIERO R, BERLOVE D, BREZZANI A, et al: Lanthanum deposition in tissues of renal compromised rats fed lanthanum carbonate for 28 days. J Am Soc Nephrol 14:205 A, 2003
25. DAMMENT SJP, GILL M: The pharmacokinetics and tissue distribution of lanthanum carbonate (Fosrenol ®). J Am Soc Nephrol 14:204, 2003
26. BEHETS GJ, DAMS G, VERCAUTEREN SR, et al: Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 15:2219-2228, 2004
27. KOWDLEY KV: Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 127:S79-S86, 2004
28. BREWER GJ: Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment. CNS Drugs 10:185-192, 2005
29. LOUDIANOS G, GITLIN JD: Wilson's disease. Semin Liver Dis 20:353-364, 2000
30. WAALKES MP: Cadmium carcinogenesis. Mutat Res 533:107-120, 2003
31. ITTEL TH, KLUGE R, SIEBERTH HG: Enhanced gastrointestinal absorption of aluminium in uraemia: Time course and effect of vitamin D. Nephrol Dial Transplant 3:617-623, 1988